Celgene Corporation (NASDAQ:CELG) had a weak trading session and its shares were last down at $96.86, down -2.43% or -2.45 points. The trading data also revealed that the total net flow stood at $27.2 million as the shares had $191.9 million in upticks but lost $164.7 million in downticks. The up/down ratio was 1.17. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of -1.9% in the shares.The block trade data suggests an inflow of $39.22 million in upticks and an outflow of $6.1 million in downticks. The up/down ratio for the block stood at 6.43. The net money flow for this transaction was recorded at $33.13.
The stock has recorded a 20-day Moving Average of 6.92% and the 50-Day Moving Average is 7.07%. The company shares have dropped 17.49% in the past 52 Weeks. On July 23, 2015 The shares registered one year high of $140.72 and one year low was seen on August 24, 2015 at $92.98. The 50-day moving average is $102.95 and the 200 day moving average is recorded at $105.08. S&P 500 has rallied 1.93% during the last 52-weeks.
Celgene Corporation (NASDAQ:CELG): The stock opened at $99.54 on Tuesday but the bulls could not build on the opening and the stock topped out at $99.80 for the day. The stock traded down to $96.31 during the day, due to lack of any buying support eventually closed down at $96.86 with a loss of -2.45% for the day. The stock had closed at $99.29 on the previous day. The total traded volume was 8,436,974 shares.
Currently the company Insiders own 0.96% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.05% . Institutional Investors own 81.31% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -24.94%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Kaplan Gilla, director of Celgene Corp /De/, had unloaded 15,967 shares at an average price of $101.84 in a transaction dated on April 4, 2016. The total value of the transaction was worth $1,626,079.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.